Bavarian Nordic Boosts Mpox Vaccine Production Amid Rising Global Demand

Bavarian Nordic, a Danish biotech firm, announced it could supply 13 million doses of its mpox vaccine by the end of 2025, up from an earlier forecast of 10 million. The company is also exploring ways to enhance production capacity by up to 50 million doses within the next 12-18 months, pending regulatory approval and market need.

Bavarian Nordic, a Danish biotech company, announced on Thursday that it could supply 13 million doses of its mpox vaccine by the end of 2025, surpassing its previous projection of 10 million doses.

The company also revealed that it had identified strategic measures to potentially increase supply by an additional 50 million doses within the next 12 to 18 months, contingent on regulatory approvals and market demand.

The company stated, "The Company continues to explore additional levers that could further expand the capacity. This includes looking to transfer manufacturing to other companies either in Africa or other parts of the world."

(With inputs from agencies.)